Obesity is epidemiologically linked to 13 forms of cancer. The local and systemic obese environment is complex and likely affect tumors through multiple avenues. This includes modulation of cancer cell phenotypes and the composition of the tumor microenvironment. A molecular understanding of how obesity links to cancer holds promise for identifying candidate genes for targeted therapy for obese cancer patient. Herein, we review both the cell-autonomous and non-cell-autonomous mechanisms linking obesity and cancer as well as provide an overview of the mouse model systems applied to study this.

Cells maintain their cytosolic calcium (Ca²⁺) in nanomolar range and use controlled increase in Ca²⁺ for intracellular signaling. With the extracellular Ca²⁺ in the millimolar range, there is a steep Ca²⁺ gradient across the plasma membrane (PM). Thus, injury that damages PM, leads to a cytosolic Ca²⁺ overload, which helps activate PM repair (PMR) response. However, in order to survive, the cells must cope with the Ca²⁺ overload. In a recent study (Chandra et al. J Cell Biol,doi: 10.1083/jcb.202006035) we have examined how cells cope with injury-induced cytosolic Ca²⁺ overload. By monitoring Ca²⁺ dynamics in the cytosol and endoplasmic reticulum (ER), we found that PM injury-triggered increase in cytosolic Ca²⁺ is taken up by the ER. Pharmacological inhibition of ER Ca²⁺ uptake interferes with this process and compromises the repair ability of the injured cells. Muscle cells from patients and mouse model for the muscular dystrophy showed that lack of Anoctamin 5 (ANO5)/Transmembrane protein 16E (TMEM16E), an ER-resident putative Ca²⁺-activated chloride channel (CaCC), are poor at coping with cytosolic Ca²⁺ overload. Pharmacological inhibition of CaCC and lack of ANO5, both prevent Ca²⁺ uptake into ER. These studies identify a requirement of Cl^– uptake by the ER in sequestering injury-triggered cytosolic Ca²⁺ increase in the ER. Further, these studies show that ER helps injured cells cope with Ca²⁺ overload during PMR, lack of which contributes to muscular dystrophy due to mutations in the ANO5 protein.